$244 Million

Akouos

Initial Public Offering

Bookrunner, June 2020

Akouos, Inc. is a precision genetic medicines company focused on development and commercialization of gene therapies for the treatment of serious inner ear disorders. The Company has built a precision genetic medicine platform that incorporates a proprietary vector library consisting of variants of a small virus commonly used in gene therapy, known as adeno-associated virus, or AAV, and a novel delivery approach. The Company’s lead product candidate, AK-OTOF, is being developed for the treatment of sensorineural hearing loss due to mutations in the otoferlin, or OTOF, gene. Apart from AK-OTOF, Akouos’ diversified portfolio of product candidates and development programs has been selected to leverage its platform across multiple inner ear disorders.

More Like This

Jul 2020
$144 Million

Initial Public Offering

Sole Bookrunner

View Details
Jun 2020
$213 Million

Initial Public Offering

Bookrunner

View Details
Jun 2020
$253 Million

Initial Public Offering

Bookrunner

View Details